Pulmonary arterial hypertension (PAH), a condition characterized by pulmonary vasculature constriction and remodeling, involves dysregulation of the serotonin (5-HT) receptors 5-HT 2A and 5-HT 2B . A rat model of monocrotaline (MCT)-induced PAH was used to examine the potential beneficial effects of RP5063, a 5-HT receptor modulator. After a single 60 mg/kg dose of MCT, rats were gavaged twice-daily (b.i.d.) with vehicle, RP5063 (1, 3, or 10 mg/kg), or sildenafil (50 mg/kg) for 28 days. RP5063 at a dose as low as 1 mg/kg, b.i.d. reduced pulmonary resistance and increased systemic blood oxygen saturation. The highest dose of RP5063 (10 mg/kg, b.i.d.) reduced diastolic, systolic, and mean pulmonary pressure, right systolic ventricular pressure, ventilatory pressure, and Fulton's index (ratio of right to left ventricular weight). Doses as low as 3 mg/kg RP5063, b.i.d. also increased weight gain and body temperature, suggesting an improvement in overall health of MCT-treated animals. Similar reductions in pulmonary, right ventricular, and ventilatory pressure, pulmonary resistance, and Fulton's index as well as increased systemic blood oxygen saturation were observed in animals treated with the reference agent sildenafil at a higher dose (50 mg/kg, b.i.d.). Histological examination revealed that RP5063 produced dose-dependent reductions in pulmonary blood vessel wall thickness and proportion of muscular vessels, similar to sildenafil. RP5063 completely blocked MCT-induced increases in the plasma cytokines TNFα, IL-1β, and IL-6 at all doses. In summary, RP5063 improved pulmonary vascular pathology and hemodynamics, right ventricular pressure and hypertrophy, systemic oxygen saturation, and overall health of rats treated with MCT.
RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats Pulmonary arterial hypertension (PAH) is a debilitating condition characterized by increased pulmonary vascular resistance leading to right ventricular (RV) failure and death (Frumkin, 2012) . PAH has an estimated prevalence between 15 and 50 cases per 1 million (Peacock et al., 2007) . Approximately 35% of PAH patients experience some type of comorbid mental disorder (Lowe et al., 2004; Verma et al., 2016) . Survival rates are 57% and 49% at 5 and 7 years post-diagnosis, respectively (Benza et al., 2012) .
PAH occurs when the pulmonary arteries have narrowed, thickened, or become blocked due to constriction and remodeling (McLaughlin et al., 2009) . Its underlying etiology is complex (Galie et al., 2009; McLaughlin et al., 2009 ). All types of PAH share the early occurrence of endothelial dysfunction, which leads to pathologic changes that can include proliferation of endothelium and smooth muscle tissue, remodeling of pulmonary arteriole walls, impaired production of vasodilators, and overexpression of vasoconstrictors (Kamar et al., 2016) .
Several pathways are targets for pharmacologic intervention: 1-decreasing the increased expression of phosphodiesterase 5 (PDE-5); 2-antagonizing endothelin; and 3-providing exogenous prostacyclins (Corbin et al., 2005; Christman et al., 1992; Galie et al., 2004; Humbert et al., 2004a Humbert et al., , 2004b . Present treatments fail to stem the ongoing cytoproliferative processes causing modification of the pulmonary vascular structure that leads to the progression of the disease (Zopf et al., 2011) . Thus, new therapies need to modulate pulmonary vascular tone and prevent the underlying vascular remodeling and inflammatory/fibrotic processes influencing PAH development and progression.
The role of serotonin (5-HT) appears to be of particular interest. 5-HT contributes to the proliferative and functional components of PAH pathogenesis (West et al., 2016; Esteve et al., 2007; MacLean and Dempsie, 2010) . Pulmonary arteries express 5-HT 1B, 5-HT 2A, 5-HT 2B , and 5-HT 7 receptors (Shacham et al., 2006) . Its presence in the pulmonary circulation activates vascular smooth muscle (VSM), 5-HT 2A and 5-HT 2B receptors in particular, and the 5-HT transporter (SERT) to cause constriction and proliferation of pulmonary VSM cells (Dumitrascu et al., 2011; Zopf et al., 2011) .
Mice deficient in SERT or the 5-HT 1B or 5-HT 2B receptor are protected from experimental hypoxic PAH indicating that these serotonergic proteins may be targeted to treat PAH (Eddahibi et al., 2000; Launay et al., 2002; Keegan et al., 2001) . Pharmacological approaches using 5-HT 2B antagonists are effective in treating experimental PAH in rodents, suggesting potential clinical benefit in humans (Zopf et al., 2011; West et al., 2016) .
RP5063 is a multimodal modulator of dopamine and 5-HT receptors (Cantillon et al., 2017) . It possesses a high binding affinity for 5-HT 1A (1.5 nM), 5-HT 2A (2.5 nM), 5-HT 2B (0.19 nM), and 5-HT 7 (2.7 nM) receptors, and moderate affinity for the SERT (107 nM) (Cantillon et al., 2017) . Its pharmacokinetic, safety, efficacy, and patient acceptance data have been encouraging during phase 1 and 2 evaluation (Cantillon et al., 2017) . RP5063 represents a promising addition to the management of PAH.
The present study was designed to assess the efficacy of RP5063 at different dose levels in the monocrotaline (MCT)-induced PAH rat model.
Materials and methods

Experimental design
In this parallel-design study, 55 male Wistar-Kyoto rats (weights: 200-250 g; ages: 10-12 weeks; Charles River Laboratories, St Constant, Quebec, Canada) were randomized according to their body weight into six experimental groups: five groups of 10 (MCT-induced) and one group (non-induced) of five. The study schedule was such that an equal number of animals per treatment group were monitored and processed on each terminal surgery day.
The institutional animal ethics committee of IPS Therapeutique (IPST) approved the study in accordance with the principles of the Canadian Council on Animal Care (CCAC). IPST identified, housed, and cared for the animals per the CCAC guidelines.
On Day 0, dimethyl sulfoxide (DMSO; Sigma-Aldrich Canada Ltd., Oakville, Ontario, Canada) solution (0.5 ml) was injected into five healthy animals in Group 1, and MCT solution (25 mg/ml diluted in DMSO, Sigma-Aldrich Canada Ltd.) dosed at 60 mg/kg was administered to 50 animals, divided into Groups 2-6, with each group consisting of 10 animals. Treatments in Groups 2-6 (10 animals per group) were initiated on Day 0 and continued until Day 27. During this period, rats were administered twice daily (b.i.d.) via oral gavage one of the following: 1-Group 2, vehicle (5% glucose solution; IPST, Sherbrooke, Quebec, Canada) as the negative control; 2-Groups 3-5, RP5063 (Batch GP13DPBF01, Reviva Pharmaceuticals, Inc., Santa Clara, CA), dosed at 1, 3, and 10 mg/kg, RP-1, RP-3 and RP-10 respectively; or 3-Group 6, sildenafil (mesylate salt, Genemed Synthesis Inc., San Antonio, TX), the positive control, dosed at 50 mg/kg b.i.d. .
RP-1, -3, and -10 were prepared by dissolving 30, 90, or 300 mg of active drug into 400 ml of sterile 5% glucose solution, resulting in solutions of 0.075, 0.225, and 0.75 mg/ml, respectively. For Sil-50, 1895 mg of active drug was dissolved in 500 ml of sterile 5% glucose solution to obtain a solution of 3.79 mg/ml. To deliver the vehicle or treatment, investigators administered 13.33 ml/kg (2.7-3.3 ml/animal/body weight) of the resultant solutions b.i.d.
During the treatment period, rats were given food and water ad libitum. They were observed daily for behavior and general health status, and had blood samples, body weights, and body temperature weekly.
On Day 28, anesthetized animals were instrumented. Hemodynamic parameters were recorded continuously for at least 5 min or until loss of quality in the pulmonary arterial pressure (PAP) signal. These recordings involved moving a flexible catheter attached to a pressure transducer from the RV cavity, through the pulmonary valve, into the pulmonary artery and observing the clear transitions in diastolic pressures and general pressure waveforms, as the catheter transitioned from the ventricle into the artery. At the end of the recording, a blood sample was collected. After the animal was exsanguinated, the pulmonary circulation was flushed with 0.9% NaCl, and tissues were harvested for further analysis.
Parameters measured on surgery day
On Day 28, a variety of parameters were obtained. Cardiac activity was monitored using three electrocardiographic (ECG) contact electrodes (Harvard BioSciences Inc., Holliston, MA) placed in a lead-I/II configuration and connected to an IsoDam8 differential amplifier (World Precision Instruments, LLC, Sarasota, FL). Heart rate was recorded using duplicate systems: from the ECG records (RR-intervals) and using an N-595 pulse oximeter (Nellcor/Medtronic, Fridley, MN) attached to the left front paw of the animal. Blood oxygen saturation was measured using a pulse oximeter signal attached to the left front paw of the animal.
Systemic arterial blood pressure (SAP) was monitored using an intra-arterial fluid-filled catheter connected to a pressure transducer (AD Instruments, Colorado Springs, CO), with diastolic and systolic pressures values measured in mmHg using the Clampfit 10.2.0.14 (Axon Instrument Inc., Foster City, California, USA, [now Molecular Devices Inc.]). Calculation of mean SAP (mSAP) and pulse pressure involved the following formulas: 1-mSAP = diastolic pressure + ([systolic pressure -diastolic pressure] / 3); and 2-pulse pressure = systolic pressure -diastolic pressure.
RV systemic pressure (RVSP) and PAP were measured using an intra-ventricular fluid-filled catheter connected to a pressure transducer (AD Instruments, Colorado Springs, CO). Diastolic and systolic pressures were measured in mmHg using Clampfit 10.2.0.14 readings. Calculation of mean RVSP (mRVSP) and mean PAP (mPAP) was as described for the mSAP. All hemodynamic parameters were digitized using Digidata 1440A interface (Axon Instrument Inc.), and acquired displayed using Axoscope 10.2.0.14 (Axon Instrument Inc).
Organ weights were expressed as relative percentages and were calculated as follows: Relative organ weight = (organ weight × 100) / body weight. For the Fulton's index (RV / left ventricle (LV) + septum (LV+S)) ratio was calculated as such: Fulton's index = RV weight / LV +S weight.
Histologic preparation and categorization
Trachea, lungs, and heart were removed together; the liver was extracted separately. All tissues were weighed, including the right and left lobes of the lung as well as the wet weights of the RV and LV+S of the heart. All tissues were fixed in 10% neutral buffered formalin (NBF).
A transversal section of the middle left lobe was cut and forwarded in 10% NBF to the Institute for Research in Immunology and Cancer (Montreal, Quebec, Canada). Tissue were embedded, sliced (5-µm thickness), mounted, and conventionally stained with hematoxylin and eosin. Glass slide tissue was then visualized at 200 × magnification (Eclipse T100 microscope, Nikon, Melville, NY). At least 15 nonoverlapping view fields/lung were selected for microphotographs (Nikon DS-Fi1 digital camera with Nikon NIS Elements 4.30, Nikon, Melville, NY).
All vessels in a tissue section were analyzed, from largest to smallest, with no threshold or limit set in vessel size. Intra-acinar vessels were included. Vessels associated with terminal bronchioles and all larger airways were excluded. Vessels were divided based on lumen diameter: 1-small (10-50 µm); 2-medium (50-100 µm); and 3-large ( > 100 µm). Vessels were categorized based on muscularity: 1-complete, defined as coverage greater than 90% circumference surrounded by a smooth muscle layer; 2-partial, defined as coverage between 10% and 90% circumference surrounded by a smooth muscle layer, along with a crescent of smooth muscle and two elastic laminae for part of the circumference; and 3-non-muscular, defined by a single elastic lamina for the entire circumference ( < 10%) of the vessel with no apparent smooth muscle layer.
Cytokine quantification
Blood samples were obtained on Days 0 (pre-induction), 7, 14, 21, and 28. The sample on Day 28 was collected immediately following completion of the hemodynamic measurements. One-half of each sample was saved for analysis of tumor necrosis factor (TNF) α, interleukin (IL) 1β, and IL-6. The blood was centrifuged (1000×g for 10 mins) to obtain plasma, which was stored frozen until all the samples had been collected. TNF-α, IL-1β, and IL-6 were detected by quantitative enzyme-linked immunosorbent assay using commercially available kits (TNF-α and IL-1β from Abcam, Cambridge, UK; IL-6 from Qiagen, Venlo, Netherlands). All circulating levels were extrapolated from their respective standard curves. All tests were either colorimetric or fluorescence-based.
Statistics
Values were calculated as means ± standard error of means (S.E.M.). Repeated unpaired Student t-tests using Excel 2007 (Microsoft, Redmond, WA) and GraphPad Prizm 6.0 (GraphPad Software Inc., La Jolla, CA) were performed on all experimental conditions. Comparisons included: 1-MCT + vehicle (MCT+Veh; Group 2) versus non-induced healthy animals (No-MCT; Group 1) to confirm the successful induction of the disease; and 2-treatment (Groups 3-6) versus MCT+Veh (Group 2). No comparisons were made between the RP5063 and sildenafil groups.
Results
Animal disposition
Of the 55 animals, 49 were included in the final analysis. One animal in the MCT+Veh group expired during the 28-day treatment period. Two animals in the RP-1 group died during the 28-day treatment period (Days 25 and 27). One animal in the RP-10 group was insensitive to treatment. Follow-up of records identified that this animal was highly aggressive, making it difficult to handle while administering the drug. In light of the results in the RP-10 group, and following a Dixon Q test performed on the data, this animal was considered an outlier, and all data from this animal were removed from the analysis.
3.2. Systemic hemodynamic and cardiac parameters (day 28, surgery) Table 1 summarizes the systemic hemodynamic and cardiac parameters at the time of surgery. Mean and diastolic arterial pressures and heart rate did not differ among groups. With respect to pulse pressure, the MCT+Veh group was lower by 26.74% versus the No-MCT group (P < 0.05). The RP-10 group displayed a higher pulse pressure versus the MCT+Veh control and No-MCT groups by 67.15% (P < 0.001) and 22.46%, respectively. With respect to SAP, the RP-10 group was 19.59% (P < 0.05) higher than the vehicle and 18.19% greater than the No-MCT group.
Pulmonary hemodynamic parameters (day 28, surgery)
Fig. 1A-D illustrates pulmonary hemodynamic parameters at surgery: systolic PAP (PAP Syst ), diastolic PAP (PAP Diast ), mPAP, and RVSP. The MCT+Veh group showed increases in each of these parameters (P < 0.01). Compared with the healthy animals in the non-induced group, those in the MCT-induced group who received vehicle showed higher PAP Diast (11.4-21.1 mm Hg; Δ 85%; P < 0.01) and PAP Syst (26.7-64.0 mm Hg; Δ 139%; P < 0.001).
Animals in the RP-10 and Sil-50 groups both demonstrated reductions in all hemodynamic parameters versus the MCT+Veh group. Animals in the RP5063 and Sil-50 groups showed reductions in PAP Syst of 32.8% and 30.0%, respectively (P < 0.01 for both), and PAP Diast of 30.4% and 21.3%, respectively (P < 0.05 for both). The RP5063 group reflected reductions PAP Diast and PAP Syst to 14.7 and 43.0 mm Hg, respectively (P < 0.01 for both), and the Sil-50 group showed reductions of 16.6 and 43.5 mm Hg, respectively (P < 0.05 for both). Both the RP5063 and Sil-50 groups demonstrated mPAP reductions of 31.9% and 27.9% (P < 0.01 for both), respectively, and RVSP reductions of 33.8% and 30.6%, respectively (P < 0.01 for both). As compared with the vehicle group, the RP5063 group produced reductions in mPAP and RVSP to 24.1 and 43.1 mmHg, respectively (P < 0.01 for both), and the Sil-50 group produced reductions of 25.5 and 45.2 mmHg, respectively (P < 0.001 for both). Fig. 2 highlights the respiratory parameters of the animals at the time of surgery, including oxygen saturation, respiratory resistance, and ventilatory pressure. Differences were observed between the MCT +veh and No-MCT groups with respect to oxygen saturation (reduction of 9.1%; P < 0.01) and respiratory resistance (increase of 78.6%; P < 0.01). No differences were noted in ventilatory pressure.
With respect to oxygen saturation, RP5063 realized increases in all dose groups (P < 0.05). Improvements of 6.1%, 5.6%, and 9.0% versus the vehicle group were observed in the RP-1, -3, and -10 groups, respectively. In the Sil-50 group, the improvement was 7.8% (P < 0.05). With respect to respiratory resistance, significant decreases were observed with RP-3 and RP-10 groups versus the vehicle group, with decreases of 20.9% and 48.8%, respectively (P < 0.05 for RP-3; P < 0.001 for RP-10). In the Sil-50 group, the reduction was 46.9%. With respect to ventilatory pressure, both the RP-10 and the Sil-50 groups showed reductions with decreases of 15.6% and 19.7%, respectively. Table 2 depicts body temperature, weight gain, and relative lung, liver, and trachea weights. Differences between vehicle and No-MCT groups were noted in body temperature (13.0% lower; P < 0.001), weight gain (89.1% lower; P < 0.001), and lung weight (78.2% higher).
Systemic parameters
The RP-3 and RP-10 and Sil-50 groups gained less weight versus the No-MCT group by 64.4%, 64.1%, and 64.1%, respectively (P < 0.01). The RP5063 weights were higher than the MCT+Veh by 227.1% (P < 0.05) and 230% in the RP-3 and RP-10 groups, respectively. The weights of the Sil-50 group were lower by 202.8% (P < 0.05). Body temperatures for the RP-3 and RP-10 and Sil-50 groups were higher than those in the MCT+Veh group by 2.3%, 4%, and 2.3%, respectively (P < 0.05). Compared with the MCT+Veh group, the liver weights in the RP-10 and Sil-50 groups were higher by 9.9% and 13.9%, respectively (P < 0.05). Trachea weights were lower by 15% in the RP-10 group and higher by 15% in the Sil-50 group (P < 0.05). Table 3 and Fig. 3A highlight the effect of treatment on the percentage of muscular vessels, semi-muscular vessels, and nonmuscular vessels. Differences were noted between the vehicle and No-MCT groups with respect to percentage of smooth muscle tissue (70.05%; P < 0.001) and percentage of non-muscular tissue (-67.5%; P < 0.001). With respect to muscular tissue, RP5063-treated animals had a lower percentage than the MCT+Veh group by -18.6%, -25.62%, and -34.34% in the RP-1, -3, and -10 groups, respectively (P < 0.001). The Sil-50 group showed a lower percentage of muscular tissue by -42.2% (P < 0.001). With regard to non-muscular tissue, RP5063 displayed a lower percentage than the vehicle by -19.4%, 24.61%, and 32.06% in the RP-1, -3, and -10 groups, respectively (P < 0.001). The Sil-50 group reflected a higher percentage of non-muscular tissue by 38.95% (P < 0.001). No differences were observed between the RP5063 and Sil-50 groups. Fig. 3B illustrates the effect of treatment on vessel wall thickness. Small and medium wall thicknesses were greater in the MCT+Veh group versus the No-MCT induced group (P < 0.001). With respect to treatment, the wall thicknesses for small and medium vessels were less for RP-3 (p < 0.05) and RP-10 (P < 0.001) groups and for the Sil-50 group versus the MCT+Veh group (P < 0.001). Fig. 4A -D highlights the effects of RP5063 on TNF-α, IL-1β, and IL-6. For TNF-α, and IL-β, all dose groups of RP5063 showed lower levels (non-significant) of these inflammatory cytokines when compared with the MCT+Veh group. Only in the IL-6 group did the RP-10 group show statistical significance (p < 0.05) at the Day 14 and 21 time points.
Histological findings
Cytokine findings
Discussion
MCT-induced PAH
The rat MCT-induced PAH model has been used to evaluate the effects of compounds in the prevention and treatment of PAH tion and obstruction of the pulmonary arterioles. The acute toxic injury stimulates a tissue reaction during a three-week time span that replicates an indolent human disease that then progresses over several years (idiopathic PAH). This process facilitates tissue remodeling and vasoconstriction, blood flow restriction through the pulmonary arteries, increased PAP and RV afterload and hypertrophy (Lalich et al., 1977) . All MCT-induced animals in the vehicle group developed PAH.
Compared with healthy animals, those in the vehicle group showed statistically higher pulmonary pressures, leading to RV afterload and hypertrophy, as observed by the increase in the Fulton's index. The decrease in oxygen saturation in this group confirmed that PAH affects systemic oxygenation. Compared with those in the non-induced group, the heavier weights of the lungs in the vehicle group suggested lung edema, fibrosis, or both. By contrast, the heart rate and systolic, diastolic, and mSAP were unchanged. The induction of MCT and vehicle administration did not alter the distribution of vessels based on size. Muscular arterioles (81%) RP-1, -3, and -10 -RP5063 at 1, 3 and 10 mg/kg b.i.d., MCT -monocrotaline, S.E.M. -standard error of measurement. a P < 0.001; as compared to No-MCT. b P < 0.001; as compared to MCT+Veh.
dominated the composition of the lung tissue in the MCT+Veh group, which contrasted the predominance of non-muscular arterioles (79%) in the No-MCT group. In the MCT+Veh group, the muscular layer was significantly greater in small-and medium-sized vessels. These morphologic changes patterned the functional changes of PAH.
RP5063 pharmacologic, structural, and functional effects
RP5063 is able to modulate the effects of 5-HT in the pulmonary vasculature due to its moderate affinity for SERT and high affinity for 5-HT 2A, 5-HT 2B, and 5-HT 7 receptors (Cantillon et al., 2017) . RP5063 prevented vasoconstriction possibly by 5-HT 2A signaling and mitigated cell proliferation and vascular remodeling facilitated by 5-HT 2B signaling following MCT induction (Dumitrascu et al., 2011; Farber and Loscalzo, 2004) .
During this study, all doses of RP5063 showed lower levels of TNF-α, IL-β, and IL-6, versus MCT+Veh, on Days 14, 21, and 28. In particular, IL-6 was statistically significant at the 10 mg/kg b.i.d. dose. These effects suggest that RP5063 may exert an additional mechanism. Inflammatory cytokines in idiopathic PAH play a role in PAH development, vascular cell proliferation, and remodeling of the pulmonary arteries (Humbert et al., 1995; Itoh et al., 2006; Prince et al., 2012; Soon et al., 2010) . One analysis reports that IL-6, IL-8, IL-10, and IL-12 can predict survival (Soon et al., 2010) . Hence, modulation of these factors may offer a complementary mechanism that influences tissue remodeling and other clinical sequelae.
RP-10 limited structural changes in pulmonary vasculature, which supported its blood vessel dilatory effects. These actions can prevent significant hemodynamic consequences. RP5063 at 10 mg/kg prevented elevations in PAP, RVSP, and the Fulton's index observed in the MCT+Veh group. The respiratory resistance in the RP-3 and RP-10 groups were statistically lower than in the MCT+Veh group, with the RP-10 group showing normal values. The oxygen saturation was also significantly higher in this group versus the MCT+Veh group. These hemodynamic effects were similar to those observed in the No-MCT group, suggesting that RP5063 at 10 mg/kg b.i.d. allowed for almostnormal blood flow through the pulmonary arteries.
RP5063 reflected a dose-dependent response in the distribution of vessels in the lungs. Animals in the RP-10 group displayed the lowest percentage of muscular vessels at 47% and the highest percentage of non-muscular vessels at 43%. Furthermore, wall thicknesses in small vessels in the RP-1, -3, and -10 groups, and in medium vessels in the RP-3 and RP-10 groups, were statistically lower than those in the MCT +Veh group.
A.
B. 
Sildenafil effects
Sildenafil imparts its actions by relaxing pulmonary vessel smooth muscles and causing vasodilation (Barnett and Machado, 2006) . In the present study, sildenafil served as a reference compound. The group assigned to sildenafil had statistically lower pulmonary pressures versus the MCT+Veh group. The systolic, diastolic, and mPAP values were similar to those seen in the No-MCT group. Sildenafil significantly limited increases in systolic ventricular pressure and the Fulton's index seen in the MCT+Veh group, suggesting a preventive effect on RV hypertrophy. Alternatively, sildenafil did not prevent the changes in lung weight, which suggest lung fibrosis, associated edema, or both. The ventilatory pressure was significantly lower in the sil-50 group compared with the MCT+Veh group.
Although sildenafil did not alter the distribution of vessels based on size, it did alter vessel composition. Sildenafil prevented the development of smooth muscle and non-muscular arterioles, predominately (50.4%) the composition of the lung tissue. These findings suggest that sildenafil prevented the hyperplasia caused by sustained contraction.
Sil-50 was not statistically different from RP-10 in pulmonary and systolic pressures, ventilatory resistance, and Fulton's index. This observation of comparable efficacy at a five-fold lower dose might suggest a difference between these treatments relative to drug exposure, pharmacodynamics, and amplitude of benefit within the pulmonary vasculature. This study was not designed to examine the pharmacokinetic, pharmacodynamic, or clinical differences between these treatments at these doses. Further investigation is needed.
Role of RP5063 in combination therapy for PAH
PAH remains a progressive condition with a poor prognosis. Current treatments focus on addressing smooth muscle tone to enhance dilation to improve hemodynamics. Most do not address the ongoing cytoproliferative processes that modify the pulmonary vascular structure. RP5063 could provide significant benefit by suppressing the underlying structural processes associated with idiopathic PAH by mitigating the influence of 5-HT on 5-HT 2A and 2B receptors that facilitate cellular proliferation and remodeling within the pulmonary vasculature and by lowering IL-1β, IL-6, and TNF-α levels that can contribute to structural changes. Considering that current treatments focus on different pathways, RP5063 might provide significant value by suppressing the underlying structural processes associated with this condition.
Hence, future investigations should evaluate the contribution of RP5063 in combination with one of the other treatment modalities in a preclinical model, such as MCT. One approach could involve combining RP5063 with any of the three classes of PAH drugs available, as either a two-drug or three-drug combination: 1-endothelin receptor antagonists; 2-PDE-5 inhibitors; and 3-exogenous prostacyclin and analogs.
Evaluating the link between PAH and mental disorders
Approximately 35% of patients with pulmonary hypertension exhibit some form of mental disorder (Lowe et al., 2004; Verma et al., 2016) . Studies have reported acceptance of risk of death, anxiety, cognitive sequela, depression, panic disorder, memory deficits, and work disability among such individuals (Harzheim et al., 2013; Looper et al., 2009; Lowe et al., 2004; McCollister et al., 2010; Shafazand et al., 2004; White et al., 2001) . Several noted concurrent use of antidepressants in 25% and antipsychotics in 24.1% of PAH patients (Lowe et al., 2004; McCollister et al., 2010) . As dysregulation of brain serotonergic pathways plays a central role in mood and psychotic disorders (e.g., major depressive and bipolar disease) (Yuen et al., 2005) , it is possible that there is an underlying imbalance in serotonergic function linking mental disorders with PAH.
Despite the clear involvement of serotonergic pathways in the common symptoms of schizophrenia, the exact role of 5-HT remains unclear (Amato, 2015) . Clinical imaging studies find correlations between low cortical 5-HT levels and the positive and cognitive symptoms of schizophrenia. Typical and several atypical antipsychotic drugs reduce brain 5-HT, although some atypical antipsychotics increase brain 5-HT levels (Amato, 2015) . Polymorphisms in the 5-HT 1A, 2A, and 2B receptors are associated with the development and symptomatology of the major psychotic diseases (Baou et al., 2016; McMahon and Cunningham, 2001 . mRNA levels of the 5-HT 1A and 2A receptors are decreased in psychotic patients, although expression of 5-HT 1B is increased (Baou et al., 2016) . Similar changes in expression and genetic alterations in 5-HT signaling proteins have been observed in PAH. A SERT polymorphism (Zhang et al., 2013) and increased expression of the 5-HT 2B receptor (Zopf et al., 2011) are associated with PAH. Based on these genetic disease associations and the changes in the expression of serotonergic proteins in both schizophrenia and PAH, it is tempting to speculate that there may be a common mechanism underlying both disease states. Whether or not these conditions are linked pathophysiologically, a single drug with an appropriate profile of 5-HT receptor subtype modulation offers the potential to treat both diseases in comorbid patients. This realization may lead to evaluating PAH treatments for both their functional hemodynamic and psychiatric effects. In this regard, evaluation of RP5063 effects on comorbid mental disorders in PAH patients is a promising direction, as it has a favorable efficacy and safety profile in a phase 2 trial in patients with schizophrenia and schizoaffective disorders (Cantillon et al., 2017) . Robust efficacy was seen in psychotic positive symptoms (e.g., delusions) and negative symptoms (e.g., lack of motivation), along with signals in depression, social function, and cognition, within a week of starting treatment (Cantillon et al., 2017) .
Conclusions
PAH is a chronic, progressive condition. Within 7 years of diagnosis, one-half of patients with PAH die while receiving the treatments currently available (Benza et al., 2012) . This study demonstrated that RP5063, a new chemical entity with a novel mechanism of action involving 5-HT receptors, prevented PAH in MCT-induced rats representative of clinical idiopathic PAH. RP5063 at 10 mg/kg b.i.d. was statistically efficacious in preventing the structural and functional effects of PAH observed in MCT+Veh group. These included: 1-improved pulmonary hemodynamics; 2-reduced RV hypertrophy; 3-restored arterial oxygenation; and 4-attenuated structural remodeling within the pulmonary blood vessels. The magnitude of the effect seen with RP-10 was comparable with that observed with Sil-50. RP5063 also suppressed increases in inflammatory cytokines during the development of PAH, thereby preventing the remodeling of the pulmonary vasculature. RP5063 represents an attractive compoundwith the potential of being a disease-modifying treatment-and needs to be explored further, either as a single agent or used in combination with existing drugs, for the treatment of PAH and associated comorbidities.
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